Sickle Cell Anemia Clinical Trial
Official title:
Phase 2 Study of Effects of Plasma Nitrite in Sickle Cell Anemia
Verified date | July 2018 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators hypothesize that increasing plasma nitrite using dietary nitrate will improve platelet function and red cell deformability and decrease MCHC in patients with sickle cell disease. The investigators will test this hypothesis through administration of daily intake of beetroot juice (Unbeetable - Performance Drink) to patients with sickle cell disease for 28 days. The investigators will evaluate the safety of daily beet root juice intake in patients with sickle cell disease. In addition, the investigators will measure MCHC, red cell deformability, and platelet function (activation and aggregation) in response to daily intake of beet root juice in this patient population.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 2019 |
Est. primary completion date | February 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: - diagnosis of sickle cell anemia (Hb S/S or Hb S/beta thal0) - no acute illness at the time of obtaining the study - willingness to adhere to the study preparatory procedures including drinking the beet juice product daily - willingness to give consent in order to participate Exclusion Criteria: - less than 19 years in age or older than 65 - smoke or chew tobacco - currently take medications that affect stomach pH - atrophic gastritis - hypo-or hyperthyroidism - Type I or II diabetes - history of gout, kidney stones or hypotension - pregnant - aversion to the study-related testing procedures - allergy, sensitivity or aversion to the study beetroot juice beverage - suffered an acute sickle cell episode (involving hospitalization or a visit to the emergency room) within the past six months |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University School of Medicine | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences | National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Number of Participants with Adverse Events as a Measure of Safety and Tolerability as a function of time | Physical symptoms will be assessed either by telephone or in person | up to 58 Days | |
Secondary | Changes in Red blood cell properties as a function of time | Blood will be drawn and used to measure red blood cell deformability and mean corpuscular hemoglobin concentration | Days 1, 14, 28 | |
Secondary | Changes in Platelet function as a function of time | Blood will be drawn and used to measure platelets activation and aggregation | Days 1, 14, 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04581356 -
Voxelotor Sickle Cell Exercise Study
|
Phase 4 | |
Completed |
NCT02712346 -
The Role of Endothelin-1 in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT01976416 -
Novel Use Of Hydroxyurea in an African Region With Malaria
|
Phase 3 | |
Completed |
NCT01137721 -
State Of The Art Functional Imaging In Sickle Cell Disease
|
||
Terminated |
NCT01350232 -
Treatment of Sickle Cell Anemia With Stem Cell Transplant
|
N/A | |
Withdrawn |
NCT00937144 -
Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil
|
Phase 4 | |
Completed |
NCT00512564 -
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
Completed |
NCT00004412 -
Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
|
Phase 2 | |
Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
Completed |
NCT01848691 -
Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
|
N/A | |
Completed |
NCT01783990 -
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
|
||
Completed |
NCT01000155 -
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
|
Phase 2 | |
Completed |
NCT00874172 -
Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy
|
N/A | |
Completed |
NCT00399074 -
Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia
|
Phase 3 | |
Completed |
NCT00236093 -
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
|
Phase 2 | |
Completed |
NCT00004492 -
Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
|
Phase 1/Phase 2 | |
Completed |
NCT02065596 -
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
|
Phase 1 |